Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models

During the development of indazolylpyrimidines as novel and potent inhibitors of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR2) tyrosine kinase, we observed that some human tumour xenografts are more sensitive to VEGFR2 kinase inhibitors than others. A better understanding of the basi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Dev, I K, Dornsife, R E, Hopper, T M, Onori, J A, Miller, C G, Harrington, L E, Dold, K M, Mullin, R J, Johnson, J H, Crosby, R M, Truesdale, A T, Epperly, A H, Hinkle, K W, Cheung, M, Stafford, J A, Luttrell, D K, Kumar, R
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2004
Teme:
Experimental Therapeutics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409895/
https://ncbi.nlm.nih.gov/pubmed/15328520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602109
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items